comparemela.com

Latest Breaking News On - Division of hematological malignancies - Page 1 : comparemela.com

Ajax Therapeutics Appoints Dr David Steensma as Chief Medical Officer

NEW YORK (BUSINESS WIRE) Aug 23, 2023

United statesKathryn morrisDavid steensmaRoss levineMartin vogelbaumLaurence joseph dineenEdwardp evansDavidp steensmaHarvard medical schoolTranslational researchDivision of hematological malignanciesNovartis institutes for biomedical researchDana farber cancer instituteDivision of hematologyDepartment of medicineInstitute physician

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics with.

United statesMiltonh wernerAlex loboMilton wernerDivision of hematological malignanciesInhibikase therapeutics incCompany contactMovement disorders society congressDrug administrationExchange commissionPrnewswire inhibikase therapeutics incInhibikase or companySternir incInvestigational new drugChief executive officerMultiple system

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity - Press Release

Company to host conference call and webcast on Monday, August 15, 2022, at 8:00am ETBOSTON and ATLANTA, Aug. 12, 2022 /PRNewswire/ Inhibikase Thera

United statesMiltonh wernerAlex loboMilton wernerDivision of hematological malignanciesInhibikase therapeutics incCompany contactMovement disorders society congressDrug administrationExchange commissionInhibikase or companySternir incInhibikase therapeuticsInvestigational new drugChief executive officerMultiple system

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesMiltonh wernerAlex loboMilton wernerDivision of hematological malignanciesInhibikase therapeutics incCompany contactMovement disorders society congressDrug administrationExchange commissionPrnewswire inhibikase therapeutics incInhibikase or companySternir incInvestigational new drugChief executive officerMultiple system

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics with.

United statesMiltonh wernerAlex loboMilton wernerDivision of hematological malignanciesInhibikase therapeutics incCompany contactMovement disorders society congressDrug administrationExchange commissionPrnewswire inhibikase therapeutics incInhibikase or companySternir incInvestigational new drugChief executive officerMultiple system

vimarsana © 2020. All Rights Reserved.